製品番号: HY-B0879

Suramin

22 Cited Publications

カスタマーレビュー

Based on 22 publication(s) in Google Scholar

Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 145-63-1
分子式: C₅₁H₄₀N₆O₂₃S₆
分子量:1297.28

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

Suramin 構造式

CAS 番号: 145-63-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (22)
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
Bioz

生物活性

製品説明

Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor^[1]. Suramin is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM)^[2]. Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM)^[3]^[4]. Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor^[5].Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent^[6]^[7]^[8].

IC₅₀ & Target^[2]

SIRT1

297 nM (IC₅₀)

SIRT2

1.15 μM (IC₅₀)

SIRT5

22 μM (IC₅₀)

Sirtuin アイソフォーム固有の製品をすべて表示 :

Topoisomerase アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	0.12 mM Compound: Suramin	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.18 mM Compound: Suramin	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
HEK293	EC₅₀	>100 μM Compound: Suramin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 27720295]
HepG2	CC₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
HepG2	CC₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
HepG2	CC₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	IC₅₀	67.4 μM Compound: Suramin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay	[PMID: 32631535]
HepG2	CC₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
HL-60	GI₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay	[PMID: 30986574]
HL-60	GI₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay Cytotoxicity against human HL-60 cells by resazurin dye based fluorescence assay	[PMID: 33071053]
HL-60	GI₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based assay	[PMID: 34968675]
HL-60	GI₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 24 hrs and measured at 48 hrs following resazurin challenge by resazurin assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 24 hrs and measured at 48 hrs following resazurin challenge by resazurin assay	[PMID: 36870272]
HL-60	GI₅₀	>100 μM Compound: Suramin	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 24 hrs by resazurin dye based microplate reader analysis Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 24 hrs by resazurin dye based microplate reader analysis	[PMID: 37988797]
HUVEC	IC₅₀	500 μM Compound: Suramin	Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay	[PMID: 11591505]
HUVEC	IC₅₀	500 μM Compound: Sur	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	[PMID: 22182929]
K562	IC₅₀	18.49 μM Compound: Suramin	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 22464458]
L6	IC₅₀	4724.5 μM Compound: sur	Cytotoxicity against L6 cells Cytotoxicity against L6 cells	[PMID: 16889962]
L6	IC₅₀	4725 μM Compound: Sr	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	[PMID: 25746816]
MCF7	IC₅₀	154 μM Compound: Suramin	Cytotoxicity against FGF1-stimulated human MCF7 cells cultured in serum-starved media assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay Cytotoxicity against FGF1-stimulated human MCF7 cells cultured in serum-starved media assessed as reduction in cell viability incubated for 48 hrs by WST-1 assay	[PMID: 32827875]
MDA-MB-231	IC₅₀	31.19 μM Compound: Suramin	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 22464458]
MRC5	IC₅₀	>100 μg/mL Compound: suramin	Cytotoxicity against human MRC5 cells after 7 days by MTT assay Cytotoxicity against human MRC5 cells after 7 days by MTT assay	[PMID: 19013823]
MRC5	IC₅₀	>100 μg/mL Compound: suramin	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 24388808]
MRC5	IC₅₀	>64 μM Compound: Suramin	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	[PMID: 25199582]
MRC5	IC₅₀	0.02 μM Compound: SUR	Antiparasitic activity against suramin-sensitive trypomastigote stage of Trypanosoma brucei rhodesiense squib-427 infected in human MRC5 cells after 4 days by Alamar blue staining based fluorimetric analysis Antiparasitic activity against suramin-sensitive trypomastigote stage of Trypanosoma brucei rhodesiense squib-427 infected in human MRC5 cells after 4 days by Alamar blue staining based fluorimetric analysis	[PMID: 26922226]
MRC5	EC₅₀	>64 μM Compound: Suramin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay	[PMID: 30677668]
MT4	CC₅₀	250 μM Compound: suramin	Evaluated for 50% cytotoxic concentration based on reduction of viability of mock-infected cells Evaluated for 50% cytotoxic concentration based on reduction of viability of mock-infected cells	[PMID: 1282569]
MT4	EC₅₀	8.2 μM Compound: suramin	Evaluated for 50% antiviral effective concentration based on inhibition of HIV-1 (HTLV-IIIB) induced cytopathogenicity in MT-4 cells Evaluated for 50% antiviral effective concentration based on inhibition of HIV-1 (HTLV-IIIB) induced cytopathogenicity in MT-4 cells	[PMID: 1282569]
MT4	CC₅₀	47 μM Compound: Suramin	Cytotoxicity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE) Cytotoxicity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE)	[PMID: 8336338]
MT4	EC₅₀	8 μM Compound: Suramin	Antiviral activity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE) Antiviral activity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE)	[PMID: 8336338]
Oocyte	EC₅₀	10400 nM Compound: Suramin	The compound was evaluated for antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 30 uM, expressed in Xenopus oocytes The compound was evaluated for antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 30 uM, expressed in Xenopus oocytes	[PMID: 12213051]
Oocyte	EC₅₀	>100000 nM Compound: Suramin	Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 3 uM, expressed in Xenopus oocytes Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 3 uM, expressed in Xenopus oocytes	[PMID: 12213051]
Oocyte	EC₅₀	1 μM Compound: Suramin	The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 1 (P2X1) at 1 uM, expressed in Xenopus oocytes The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 1 (P2X1) at 1 uM, expressed in Xenopus oocytes	[PMID: 12213051]
Oocyte	EC₅₀	3 μM Compound: Suramin	The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 3 (P2X2) at 10 uM, expressed in Xenopus oocytes The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 3 (P2X2) at 10 uM, expressed in Xenopus oocytes	[PMID: 12213051]
Sf9	IC₅₀	1.27 μM Compound: Suramin	Inhibition of human recombinant N-terminal His6 tagged NPP3 expressed in baculovirus infected Sf9 cell membranes using pNP-TMP as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 15 mins by colorimetric meth Inhibition of human recombinant N-terminal His6 tagged NPP3 expressed in baculovirus infected Sf9 cell membranes using pNP-TMP as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 15 mins by colorimetric meth	[PMID: 31382118]
SW1353	EC₅₀	15 μM Compound: Suramin	Induction of TIMP3 protein level in human HTB-94 cells incubated for 36 hrs by slot blotting analysis relative to 100 ug/ml suramin Induction of TIMP3 protein level in human HTB-94 cells incubated for 36 hrs by slot blotting analysis relative to 100 ug/ml suramin	[PMID: 37517101]
Vero	EC₅₀	40 μM Compound: Suramin	Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells preincubated with virus for 5 mins followed by cell infection for 5 mins by immunofluorescence analysis Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells preincubated with virus for 5 mins followed by cell infection for 5 mins by immunofluorescence analysis	[PMID: 26771861]
Vero	IC₅₀	44.02 μM Compound: Suramin	Antiviral activity against Zika virus harboring subgenomic GFP replicon infected in African green monkey Vero cells assessed as reduction in viral infection preincubated for 30 mins followed by viral infection and measured after 72 hrs Antiviral activity against Zika virus harboring subgenomic GFP replicon infected in African green monkey Vero cells assessed as reduction in viral infection preincubated for 30 mins followed by viral infection and measured after 72 hrs	[PMID: 30925051]
Vero 76	IC₅₀	5.68 μM Compound: Suramin	Antiviral activity against CHIKV infected in Vero 76 cells assessed as reduction in cytopathic effect Antiviral activity against CHIKV infected in Vero 76 cells assessed as reduction in cytopathic effect	[PMID: 38394369]

体外実験

Suramin (50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells^[7].
Suramin (300 μg/mL; for 48 hours) induces cells apoptosis, and down-regulates mRNA expression in HeLa cells^[7].
Suramin (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2^[8].
The IC₅₀ values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively^[7].
Suramin blocks viral replication in Vero E6 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[6]

Cell Line:

HO-8910 PM ovarian and Hela cervical cancer cells
Concentration:

50, 100, 200, 300, 400, 500 and 600 μg/mL
Incubation Time:

For 24, 48, 72 and 96 hours
Result:

Inhibited cells proliferation in a dose-dependent and time-dependent manner.

Apoptosis Analysis^[6]

Cell Line:

HeLa cells
Concentration:

300 μg/mL
Incubation Time:

For 48 hours
Result:

Induced cells apoptosis.

Western Blot Analysis^[7]

Cell Line:

PA-SMCs cells
Concentration:

1 mg/mL
Incubation Time:

For 1 hours
Result:

Significantly suppressed the phosphorylated ERK1/2.

体内実験

Suramin (10 mg/kg; IV; twice weekly for 3 weeks) reverses established pulmonary hypertension (PH), thereby normalizing the pulmonary artery pressure values and vessel structure^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Wistar rats (200-225 g)^[7]
Dosage:

10 mg/kg
Administration:

IV; twice weekly for 3 weeks
Result:

Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure.

化学情報

CAS 番号 145-63-1
分子量 1297.28
分子式 C₅₁H₄₀N₆O₂₃S₆
SMILES

O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O)=O)C4=CC(S(=O)(O)=O)=CC(S(=O)(O)=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O)=O)C8=CC(S(=O)(O)=O)=CC(S(=O)(O)=O)=C78)=O)=CC=C6C)=O)=CC=C5
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (22)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayCell Imaging/StainingRT-PCRIP

Sort by:

Journal Impact Factor

J Hematol Oncol

C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function. [Abstract]

2025 Apr 1;18(1):38. PMID: 40170099
Cell Metab

Dietary-timing-induced gut microbiota diurnal oscillations modulate inflammatory rhythms in rheumatoid arthritis. [Abstract]

2024 Sep 5:S1550-4131(24)00334-6. PMID: 39260371
Nat Commun

Ultrasound-mediated spatial and temporal control of engineered cells in vivo. [Abstract]

2024 Aug 27;15(1):7369. PMID: 39191796
Adv Sci (Weinh)

Stromal Cell-Mast Cell Communication Orchestrates Anti-Viral Immunity in the Meninges. [Abstract]

2025 Nov 6:e14842. PMID: 41195564
Nat Struct Mol Biol

Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. [Abstract]

2021 Mar;28(3):319-325. PMID: 33674802
Br J Pharmacol

Transient Receptor Potential channels, TRPV1 and TRPA1 in melanocytes synergize UV-dependent and UV-independent melanogenesis. [Abstract]

2021 Dec;178(23):4646-4662. PMID: 34363226
J Med Chem

Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate. [Abstract]

2024 Aug 8;67(15):12760-12783. PMID: 39072488
Clin Transl Med

Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma. [Abstract]

2021 Jun;11(6):e485. PMID: 34185429
J Agric Food Chem

Ginsenoside F4 Alleviates Skeletal Muscle Insulin Resistance by Regulating PTP1B in Type II Diabetes Mellitus. [Abstract]

2023 Oct 4;71(39):14263-14275. PMID: 37726223
Int Immunopharmacol

The immunoregulator β-glucan produces antidepressant effects through microglia-mobilized astrocytic P2Y1R-BDNF signaling in the dentate gyrus. [Abstract]

2025 Sep 6:165:115494. PMID: 40915186
Int Immunopharmacol

Suramin ameliorates osteoarthritis by acting on the Nrf2/HO-1 and NF-κB signaling pathways in chondrocytes and promoting M2 polarization in macrophages. [Abstract]

2023 Jul:120:110295. PMID: 37182454
Phys Rev Appl

2025 Jun 06.
ACS Omega

Infectious cDNA Clone of Chikungunya Virus 181/25 for Antiviral Assay Development. [Abstract]

2025 Dec 8;10(50):62145-62156. PMID: 41476561

Suramin purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Dec 8;10(50):62145-62156. [Abstract]

Suramin sodium salt (0-100 μM, 24 h) showed a dose-dependent inhibition in Vero cells when they were infected with 1 MOI of GFP-wtCHIKV.
Lipids Health Dis

Suramin, an antiparasitic drug, stimulates adipocyte differentiation and promotes adipogenesis. [Abstract]

2023 Dec 13;22(1):222. PMID: 38093311

Suramin purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]

Suramin sodium salt (35, 70, 105, and 140 µM, 2-4 days) showed no cytotoxicity at 35 and 70 µM, but exhibited a cytotoxic effect by decreasing cell viability at 105 and 140 µM in fascial preadipocytes.

Suramin purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]

Suramin sodium salt (35–140 µM, 5 days) elevated LDH release at 105 and 140 µM in fascial preadipocytes.

Suramin purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]

Suramin (70 µM, 9 days) induced adipogenic differentiation of fascial stromal preadipocytes.

Suramin purchased from MedChemExpress. Usage Cited in: Lipids Health Dis. 2023 Dec 13;22(1):222. [Abstract]

Suramin (0–70 µM, 5 days) increased the expression of adipogenic genes (left) and mature adipocyte marker gene (right) on day 5.
J Biol Chem

Type 2 diabetic mice enter a state of spontaneous hibernation-like suspended animation following accumulation of uric acid. [Abstract]

2021 Oct;297(4):101166. PMID: 34487763
J Biol Chem

Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat. [Abstract]

2020 Jul 24;295(30):10281-10292. PMID: 32493769

Suramin purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2020 Jul 24;295(30):10281-10292. [Abstract]

Suramin inhibits IP5K function in vivo. Immunoprecipitation of myc-CSN2 from myc-CSN2-HEK293 stable cell after IP5K knockdown, with or without Suramin or NF449 treatment.
Pharmacol Biochem Behav

Intranasal LAG3 antibody infusion induces microglia-dependent antidepressant effect by mobilizing astrocytic P2Y1R-mediated BDNF synthesis in the hippocampus. [Abstract]

2025 Dec:257:174114. PMID: 41106438
Biomicrofluidics

Calcium response in bone cells at different osteogenic stages under unidirectional or oscillatory flow. [Abstract]

2019 Nov 21;13(6):064117. PMID: 31768203
Behav Brain Res

Electroacupuncture-Modulated Extracellular ATP Levels in Prefrontal Cortex Ameliorated Depressive-like Behavior of Maternal Separation Rats. [Abstract]

2023 Aug 24:452:114548. PMID: 37355234
J Bone Miner Metab

Extracellular ATP-induced calcium oscillations regulating the differentiation of osteoblasts through aerobic oxidation metabolism pathways. [Abstract]

2023 Sep;41(5):606-620. PMID: 37418073
J Virol Methods

Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin. [Abstract]

2021 Dec:298:114283. PMID: 34534610
Research Square Preprint

2020 Nov.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhang YL, et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem. 1998 May 15;273(20):12281-7. [Content Brief]

[2]. Trapp J, et al. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem. 2007 Oct;2(10):1419-31. [Content Brief]

[3]. Schuetz A, et al. Structural basis of inhibition of the human NAD⁺-dependent deacetylase SIRT5 by suramin. Structure. 2007 Mar;15(3):377-89. [Content Brief]

[4]. De Clercq E, et al. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett. 1979 Nov;8(1):9-22. [Content Brief]

[5]. Wanchao Yin, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol. 2021 Mar;28(3):319-325. [Content Brief]

[6]. Jindal HK, et al. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases. Cancer Res. 1990 Dec 15;50(24):7754-7. [Content Brief]

[7]. Novaes RD, et al. Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by EnhancingParasitism, Inflammation, and Reactive Tissue Damage in Trypanosoma cruzi-Infected Mice. Oxid Med Cell Longev. 2018 Sep 30;2018:7385639. [Content Brief]

[8]. Izikki M, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS One. 2013 Oct 15;8(10):e77073. [Content Brief]

[9]. Xiaozhe Zhang, et al. Suramin and NF449 Are IP5K Inhibitors That Disrupt IP6-mediated Regulation of Cullin RING Ligase and Sensitize Cancer Cells to MLN4924/pevonedistat. J Biol Chem. 2020 Jun 3;jbc.RA120.014375. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Suramin

22 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Suramin

MedChemExpress（MCE）の使用を引用している文献 Suramin

Sirtuin アイソフォーム固有の製品をすべて表示

Topoisomerase アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (22)

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Suramin 関連分類

製品番号: HY-B0879